Drug Profile
Ibcasertib - Chipscreen Biosciences
Alternative Names: Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; Chiauranib; Chiauranib - Chipscreen Biosciences; CS-2164; IbcasertibLatest Information Update: 02 Jan 2024
Price :
$50
*
At a glance
- Originator Chipscreen Biosciences
- Class Amides; Aniline compounds; Antineoplastics; Ethers; Naphthalenes; Quinolines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Aurora kinase B inhibitors; Macrophage colony stimulating factor receptor antagonists; Mitosis inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ovarian cancer; Peritoneal cancer; Small cell lung cancer
- Phase II Graft-versus-host disease; Non-Hodgkin's lymphoma; Soft tissue sarcoma; Triple negative breast cancer
- Phase I/II Liver cancer
- Preclinical Pancreatic cancer
- No development reported Solid tumours
Most Recent Events
- 02 Jan 2024 Phase-II clinical trials in Graft-versus-host disease (PO) (Chipscreen Biosciences pipeline, January 2024)
- 02 Jan 2024 Preclinical trials in Pancreatic cancer in China (PO) (Chipscreen Biosciences pipeline, January 2024)
- 14 Aug 2023 Chemical structure Information added